You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Analysis of association between dopamine receptor genes methylation and their expression profile with the risk of schizophrenia

Kordi-Tamandani, Dor Mohammad; Sahranavard, Roya; Torkamanzehi, Adam

Psychiatric Genetics:
doi: 10.1097/YPG.0b013e328363d6e1
Original Articles
Abstract

Objective: Schizophrenia (SCZ) is a type of psychotic disorder that affects ∼1% of the population. Dopamine is one of the major neurotransmitters in the brain and its receptors are associated with a number of psychotic disorders, including SCZ. The aims of the present study were to analyze methylation and the expression profile of dopamine receptor DRD1, DRD2, DRD4, and DRD5 genes in patients with SCZ.

Materials and methods: Promoter methylation of DRD1, DRD2, DRD4, and DRD5 genes was assayed by a methylation-specific PCR in blood samples obtained from 80 SCZ cases and 71 healthy controls. Also, we investigated DRD1, DRD2, DRD4, and DRD5 mRNA levels using real-time reverse transcription PCR in 34 blood samples of healthy controls and cases.

Results: Promoter methylation of DRD4, DRD5, and DRD2 genes was statistically different in cases compared with healthy controls. The mRNA expression level results also showed statistically significant differences (P<0.0001) between cases and healthy controls for the DRD2, DRD4, and DRD5 genes, but not for DRD1.

Conclusion: Analyses of DRD genes’ methylation have highlighted the fact that the DRD gene network, overall, is actively involved in the increased risk of SCZ.

Author Information

Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran

Correspondence to Dor Mohammad Kordi-Tamandani, PhD, Department of Biology, University of Sistan and Baluchestan, PO Box 98155-987, Zahedan, Iran Tel: +98 541 2452335; fax: +98 541 2446565; e-mails: dor_kordi@yahoo.com, dor_kordi@science.usb.ac.ir

Received November 22, 2011

Accepted December 15, 2012

© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins